1. Effect and mechanism of recombinant human fibroblast growth factor 18 on osteoporosis in OVX mice.
- Author
-
Lu PY, Huang M, Shao MH, Hu JX, Ding CY, Feng YJ, Zhang M, Lin HP, and Tian HS
- Subjects
- Animals, Mice, Female, Humans, Mice, Inbred ICR, Cell Line, Fibroblast Growth Factors pharmacology, Apoptosis drug effects, Recombinant Proteins pharmacology, Ovariectomy, Osteoblasts drug effects, Oxidative Stress drug effects, Disease Models, Animal, Osteoporosis, Postmenopausal prevention & control, Cell Proliferation drug effects
- Abstract
Objectives: This study aimed to investigate the effect and the mechanism of recombinant human fibroblast growth factor 18 (rhFGF18) on postmenopausal osteoporosis., Methods: The effect of rhFGF18 on the proliferation and apoptosis of osteoblasts and the mechanism underlying such an effect was evaluated using an oxidative stress model of the MC3T3-E1 cell line. Furthermore, ovariectomy was performed on ICR mice to imitate estrogen-deficiency postmenopausal osteoporosis. Bone metabolism and bone morphological parameters in the ovariectomized (OVX) mice were evaluated., Results: The results obtained from the cell model showed that FGF18 promoted MC3T3-E1 cell proliferation by activating the extracellular signal-regulated kinase (ERK) and p38 instead of c-Jun N-terminal kinase (JNK). FGF18 also prevented cells from damage inflicted by oxidative stress via inhibition of apoptosis. After FGF18 administration, the expression level of anti-apoptotic protein Bcl-2 in the mice was upregulated, whereas those of the pro-apoptotic proteins Bax and caspase-3 were downregulated. Administering FGF18 also improved bone metabolism and bone morphological parameters in OVX mice., Conclusions: FGF18 could effectively prevent bone loss in OVX mice by enhancing osteoblastogenesis and protecting osteoblasts from oxidative stress-induced apoptosis.
- Published
- 2024
- Full Text
- View/download PDF